Oric Pharmaceuticals, Inc. — Form 10-Q
Filed November 16, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 12/100
What the filing says
This is a standard Form 10-Q filing for Oric Pharmaceuticals for the quarter ending September 30, 2026, filed November 16, 2026. The filing header and document list are provided, but the actual financial statements, MD&A, operational results, revenue figures, cash position, pipeline progress, clinical trial outcomes, or material events are not included in the text provided. Without access to the substantive content of the 10-Q, no specific dollar amounts, percentages, share counts, or concrete changes can be identified.
Why this rating
Cannot assess significance without actual 10-Q content—financials, cash burn, pipeline milestones, or material events absent from text supplied.
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.